Neuroendocrine Neoplasm Clinical Trial
Official title:
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide(18F-AlF-NOTA-octreotide ) positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).
Status | Recruiting |
Enrollment | 65 |
Est. completion date | December 30, 2020 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Histologically and/or clinically confirmed and/or suspicious of NEN. 2. Signed informed consent. Exclusion Criteria: 1. Claustrophobia (unable to accept PET/CT scanning) 2. Pregnant or breast-feeding |
Country | Name | City | State |
---|---|---|---|
China | Department of PET Center,Xiangya Hospital,Central South University | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Xiangya Hospital of Central South University |
China,
Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010 Mar;51(3):454-61. doi: 10.2967/jnumed.109.066902. Epub 2010 Feb 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 18F-AlF-NOTA-octreotide PET/CT imaging of patients with Neuroendocrine Neoplasms | The radioligand 18F-AlF-NOTA-octreotide can be used to visualize neuroendocrine neoplasms | 12 months | |
Secondary | 18F-AlF-NOTA-octreotide PET/CT prognostic factor for overall and disease specific survival | The uptake of the 18F-AlF-NOTA-octreotide in neuroendocrine neoplasm lesions (quantified as Standard Uptake Values) is associated with overall and disease specific free survival (PFS) neuroendocrine neoplasms | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
Active, not recruiting |
NCT03375320 -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 3 | |
Active, not recruiting |
NCT03980925 -
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
|
Phase 2 | |
Recruiting |
NCT02402244 -
Project: Every Child for Younger Patients With Cancer
|
||
Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
Recruiting |
NCT05879055 -
A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN
|
Phase 2 | |
Terminated |
NCT03001349 -
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
|
Early Phase 1 | |
Completed |
NCT02399215 -
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05165407 -
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC
|
Phase 2 | |
Recruiting |
NCT06337760 -
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
|
||
Recruiting |
NCT04927611 -
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
|
||
Active, not recruiting |
NCT01638533 -
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
Phase 1 | |
Recruiting |
NCT02817945 -
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
|
Early Phase 1 | |
Active, not recruiting |
NCT03950609 -
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04750954 -
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02402920 -
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04931446 -
Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis
|
||
Recruiting |
NCT06343428 -
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
|
||
Recruiting |
NCT04720391 -
Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
|
||
Recruiting |
NCT03734913 -
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
|
Phase 1 |